Vir Biotech CEO on the expanded GSK partnership

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

  • QuantumScape CEO defends its data after Scorpion Capital short report
  • Why pickleball is seeing a pandemic boom
  • Cramer’s lightning round: I’d buy Lithia Motors right here
  • CNBC Television published this video item, entitled “Vir Biotech CEO on the expanded GSK partnership” – below is their description.

    George Scangos, CEO of VIR Biotechnology, joins “Squawk Alley” to discuss the company’s expanded partnership with GlaxoSmithKline as well as Covid antibody treatments.

    CNBC Television YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • Honouring ageing Queensland soldiers this Anzac Day | 7NEWS
  • South Korea braces for possible fourth coronavirus wave amid slow vaccination drive
  • Coronavirus: Families reunite as Trans-Tasman bubble begins | 9 News Australia
  • Cape Verde governing party retains power after winning parliamentary polls
  • Coronavirus: Australians over 50 to receive COVID-19 jab | 9 News Australia
  • In This Story: GlaxoSmithKline

    GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.

    Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co.

    GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.

    The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.

    The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization‘s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.

    In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.

    2 Recent Items: GlaxoSmithKline

  • Boris Johnson hails falling infection rates in UK, but warns of third Covid wave from Europe
  • Boris Johnson announces deal to manufacture 60m doses of Novavax vaccine in UK
  • Leave a Comment